Cord blood therapy is set to take a major step forward in India, as the Super Speciality Paediatric Hospital and Post Graduate Teaching Institute (Child PGI) in Noida announced upcoming clinical trials for premature infants. This marks one of the first government initiatives in the country to explore the potential of cord blood transfusion in neonatal care.
The announcement was made during a national CME programme on “Cord Blood Transfusion Forum,” which gathered experts from India and abroad. Doctors highlighted that cord blood—usually discarded after birth—could be a safer and more effective alternative to donor blood, especially for preterm babies vulnerable to multiple transfusions.
Dr. Satyam Arora from Child PGI shared that a validation study had already confirmed feasibility, paving the way for trials in collaboration with international researchers. Experts like Dr. Enrico Lopiore from the Netherlands also emphasized that cord blood therapy is gaining global recognition for reducing risks associated with donor exposures.
Child PGI has already established advanced transfusion services, including NAT-tested blood and paediatric stem cell collection. With these trials, the institute hopes to lead India’s efforts in neonatal research, addressing the shortage of donor blood and ensuring safer treatment for fragile infants.
